Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases

被引:16
作者
Cuccia, Francesco [1 ]
Rigo, Michele [1 ]
Gurrera, Davide [1 ]
Nicosia, Luca [1 ]
Mazzola, Rosario [1 ]
Figlia, Vanessa [1 ]
Giaj-Levra, Niccolo [1 ]
Ricchetti, Francesco [1 ]
Attina, Giorgio [1 ]
Pastorello, Edoardo [1 ]
De Simone, Antonio [1 ]
Naccarato, Stefania [1 ]
Sicignano, Gianluisa [1 ]
Ruggieri, Ruggero [1 ]
Alongi, Filippo [1 ,2 ]
机构
[1] IRCCS Sacro Cuore Don Calabria Hosp, Adv Radiat Oncol Dept, Negrar Di Valpolicella, VR, Italy
[2] Univ Brescia, Brescia, Italy
关键词
MR-linac; Oligometastases; Lymph node; MRgRT; Adaptive radiotherapy; SBRT; Intra-fraction variability; BODY RADIATION-THERAPY; PROSTATE-CANCER; STEREOTACTIC RADIOTHERAPY; LINAC; PARADIGM; DISEASE;
D O I
10.1007/s00432-021-03739-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We report preliminary dosimetric data concerning the use of 1.5-T MR-guided daily-adaptive radiotherapy for abdomino-pelvic lymph-nodal oligometastases. We aimed to assess the impact of this technology on mitigating daily variations for both target coverage and organs-at-risk (OARs) sparing. Methods A total of 150 sessions for 30 oligometastases in 23 patients were analyzed. All patients were treated with MR-guided stereotactic body radiotherapy (SBRT) for a total dose of 35 Gy in five fractions. For each fraction, a quantitative analysis was performed for PTV volume, V35Gy and D-mean. Similarly, for OARs, we assessed daily variations of volume, D-mean, D-max. Any potential statistically significant change between baseline planning and daily-adaptive sessions was assessed using the Wilcoxon signed-rank test, assuming a p value < 0.05 as significant. Results Average baseline PTV, bowel, bladder, and single intestinal loop volumes were respectively 8.9 cc (range 0.7-41.2 cc), 1176 cc (119-3654 cc), 95 cc (39.7-202.9 cc), 18.3 cc (9.1-37.7 cc). No significant volume variations were detected for PTV (p = 0.21) bowel (p = 0.36), bladder (p = 0.47), except for single intestinal loops, which resulted smaller (p = 0.026). Average baseline V35Gy and D-mean for PTV were respectively 85.6% (72-98.8%) and 35.6 Gy (34.6-36.1 Gy). We recorded a slightly positive trend in favor of daily-adaptive strategy vs baseline planning for improved target coverage, although not reaching statistical significance (p = 0.11 and p = 0.18 for PTV-V35Gy and PTV-D-mean). Concerning OARs, a significant difference was observed in favor of daily-adapted treatments in terms of single intestinal loop D-max [23.05 Gy (13.2-26.9 Gy) at baseline vs 20.5 Gy (12.1-24 Gy); p value = 0.0377] and D-mean [14.4 Gy (6.5-18 Gy) at baseline vs 13.0 Gy (6.7-17.6 Gy); p value = 0.0003]. Specifically for bladder, the average D-max was 18.6 Gy (0.4-34.3 Gy) at baseline vs 18.3 Gy (0.7-34.3 Gy) for a p value = 0.28; the average D-mean was 7.0 Gy (0.2-16.6 Gy) at baseline vs 6.98 Gy (0.2-16.4 Gy) for a p value = 0.66. Concerning the bowel, no differences in terms of D-mean [4.78 Gy (1.3-10.9 Gy) vs 5.6 Gy (1.4-10.5 Gy); p value = 0.23] were observed between after daily-adapted sessions. A statistically significant difference was observed for bowel D-max [26.4 Gy (7.7-34 Gy) vs 25.8 Gy (7.8-33.1 Gy); p value = 0.0086]. Conclusions Daily-adaptive MR-guided SBRT reported a significantly improved single intestinal loop sparing for lymph-nodal oligometastases. Also, bowel D-max was significantly reduced with daily-adaptive strategy. A minor advantage was also reported in terms of PTV coverage, although not statistically significant.
引用
收藏
页码:3269 / 3277
页数:9
相关论文
共 32 条
  • [1] Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes
    Alongi, Filippo
    Rigo, Michele
    Figlia, Vanessa
    Cuccia, Francesco
    Giaj-Levra, Niccolo
    Nicosia, Luca
    Ricchetti, Francesco
    Vitale, Claudio
    Sicignano, Gianluisa
    De Simone, Antonio
    Naccarato, Stefania
    Ruggieri, Ruggero
    Mazzola, Rosario
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1117)
  • [2] 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
    Alongi, Filippo
    Rigo, Michele
    Figlia, Vanessa
    Cuccia, Francesco
    Giaj-Levra, Niccolo
    Nicosia, Luca
    Ricchetti, Francesco
    Sicignano, Gianluisa
    De Simone, Antonio
    Naccarato, Stefania
    Ruggieri, Ruggero
    Mazzola, Rosario
    [J]. RADIATION ONCOLOGY, 2020, 15 (01)
  • [3] Stereotactic body radiation therapy: The report of AAPM Task Group 101
    Benedict, Stanley H.
    Yenice, Kamil M.
    Followill, David
    Galvin, James M.
    Hinson, William
    Kavanagh, Brian
    Keall, Paul
    Lovelock, Michael
    Meeks, Sanford
    Papiez, Lech
    Purdie, Thomas
    Sadagopan, Ramaswamy
    Schell, Michael C.
    Salter, Bill
    Schlesinger, David J.
    Shiu, Almon S.
    Solberg, Timothy
    Song, Danny Y.
    Stieber, Volker
    Timmerman, Robert
    Tome, Wolfgang A.
    Verellen, Dirk
    Wang, Lu
    Yin, Fang-Fang
    [J]. MEDICAL PHYSICS, 2010, 37 (08) : 4078 - 4101
  • [4] MR-guidance in clinical reality: current treatment challenges and future perspectives
    Corradini, S.
    Alongi, F.
    Andratschke, N.
    Belka, C.
    Boldrini, L.
    Cellini, F.
    Debus, J.
    Guckenberger, M.
    Hoerner-Rieber, J.
    Lagerwaard, F. J.
    Mazzola, R.
    Palacios, M. A.
    Philippens, M. E. P.
    Raaijmakers, C. P. J.
    Terhaard, C. H. J.
    Valentini, V.
    Niyazi, M.
    [J]. RADIATION ONCOLOGY, 2019, 14 (1)
  • [5] Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac
    Dunlop, Alex
    Mitchell, Adam
    Tree, Alison
    Barnes, Helen
    Bower, Lorna
    Chick, Joan
    Goodwin, Edmund
    Herbert, Trina
    Lawes, Rebekah
    McNair, Helen
    McQuaid, Dualta
    Mohajer, Jonathan
    Nilawar, Rahul
    Pathmanathan, Angela
    Smith, Gillian
    Hanson, Ian
    Nill, Simeon
    Oelfke, Uwe
    [J]. CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 23 : 35 - 42
  • [6] Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen
    Henke, Lauren
    Kashani, Rojano
    Robinson, Clifford
    Curcuru, Austen
    DeWees, Todd
    Bradley, Jeffrey
    Green, Olga
    Michalski, Jeff
    Mutic, Sasa
    Parikh, Parag
    Olsen, Jeffrey
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 126 (03) : 519 - 526
  • [7] Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages
    Henke, Lauren
    Kashani, Rojano
    Yang, Deshan
    Zhao, Tianyu
    Green, Olga
    Olsen, Lindsey
    Rodriguez, Vivian
    Wooten, H. Omar
    Li, H. Harold
    Hu, Yanle
    Bradley, Jeffrey
    Robinson, Clifford
    Parikh, Parag
    Michalski, Jeff
    Mutic, Sasa
    Olsen, Jeffrey R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (05): : 1078 - 1086
  • [8] ROBOTIC IMAGE-GUIDED STEREOTACTIC RADIOTHERAPY, FOR ISOLATED RECURRENT PRIMARY, LYMPH NODE OR METASTATIC PROSTATE CANCER
    Jereczek-Fossa, Barbara Alicja
    Beltramo, Giancarlo
    Fariselli, Laura
    Fodor, Cristiana
    Santoro, Luigi
    Vavassori, Andrea
    Zerini, Dario
    Gherardi, Federica
    Ascione, Carmen
    Bossi-Zanetti, Isa
    Mauro, Roberta
    Bregantin, Achille
    Bianchi, Livia Corinna
    De Cobelli, Ottavio
    Orecchia, Roberto
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02): : 889 - 897
  • [9] CyberKnife: A new paradigm in radiotherapy
    Kurup, Gopalakrishna
    [J]. JOURNAL OF MEDICAL PHYSICS, 2010, 35 (02) : 63 - 64
  • [10] Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer A Systematic Review and Meta-analysis
    Lehrer, Eric J.
    Singh, Raj
    Wang, Ming
    Chinchilli, Vernon M.
    Trifiletti, Daniel M.
    Ost, Piet
    Siva, Shankar
    Meng, Mao-bin
    Tchelebi, Leila
    Zaorsky, Nicholas G.
    [J]. JAMA ONCOLOGY, 2021, 7 (01) : 92 - 106